OICR-9429

News alerts, weekly reports and conference planners

Company:

FACIT, Ontario Institute for Cancer Research, Structural Genomics Consortium

Drug class:

WDR5 inhibitor

‹

›

CEBPA mutation	Acute Myelogenous Leukemia	CEBPA mutation	Acute Myelogenous Leukemia	OICR-9429 Sensitive: D – Preclinical OICR-9429 Sensitive : D	OICR-9429 Sensitive: D – Preclinical OICR-9429 Sensitive : D
WDR5 overexpression	Bladder Cancer	WDR5 overexpression	Bladder Cancer	OICR-9429 Resistant: D – Preclinical OICR-9429 Resistant : D	OICR-9429 Resistant: D – Preclinical OICR-9429 Resistant : D

Associations
(2)